Sugi Predict

Sugi Predict / Compounds / SCHEMBL5573083

SCHEMBL5573083

SCHEMBL5573083

CC(C)(C)OC(=O)N1CCN(CO)CC1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ USP2 O75604 1/20 0.55
▸ SMN1; SMN2 Q16637 1/20 0.55
▸ CHRM2 P08172 1/20 0.50
▸ CHRM4 P08173 1/20 0.50
▸ CHRM1 P11229 1/20 0.50
▸ CHRM3 P20309 1/20 0.50
▸ NR1H2 P55055 1/20 0.47
▸ HPGD P15428 1/20 0.46
▸ EPHX2 P34913 1/20 0.45
▸ ALDH1A1 P00352 3/20 0.44
▸ MEN1 O00255 1/20 0.44
▸ KMT2A Q03164 1/20 0.44
▸ RECQL P46063 1/20 0.44
▸ EPHX1 P07099 1/20 0.44
▸ MAPT P10636 2/20 0.43
▸ NPC1 O15118 1/20 0.43
▸ MAPK1 P28482 1/20 0.43
▸ HTT P42858 1/20 0.43
▸ RAB9A P51151 1/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8242595 0.86 USP2 (0.61) USP2SMN1; SMN2CHRM2CHRM4CHRM1
SCHEMBL24671500 0.86 NR1H2 (0.44) USP2SMN1; SMN2CHRM2CHRM4CHRM1
SCHEMBL698803 0.85 USP2 (0.69) USP2SMN1; SMN2NR1H2HPGDEPHX2
SCHEMBL18294 0.85 USP2 (0.69) USP2SMN1; SMN2NR1H2HPGDEPHX2
SCHEMBL39756 0.85 USP2 (0.51) USP2SMN1; SMN2CHRM2CHRM4CHRM1
SCHEMBL863104 0.85 USP2 (0.55) USP2SMN1; SMN2CHRM2CHRM4CHRM1
SCHEMBL20742697 0.83 USP2 (0.53) USP2SMN1; SMN2CHRM2CHRM4CHRM1
SCHEMBL20873847 0.83 USP2 (0.53) USP2SMN1; SMN2CHRM2CHRM4CHRM1
SCHEMBL13645410 0.83 USP2 (0.53) USP2SMN1; SMN2CHRM2CHRM4CHRM1
SCHEMBL1306945 0.83 USP2 (0.53) USP2SMN1; SMN2CHRM2CHRM4CHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190241533-A1 NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN FORMA THERAPEUTICS, INC. 2019-08-08 — — US disclosed
EP-3180001-B1 ACTIVE METABOLITE OF 1-[(2-BROMOPHENYL) SULFONYL]-5-METHOXY-3- [(4-METHYL-1-PIPERAZINYL) METHYL]-1H-INDOLE DIMESYLATE MONOHYDRATE AND DIMESYLATE DIHYDRATE SALT OF ACTIVE METABOLITE SUVEN LIFE SCIENCES LTD (IN) 2019-01-09 — — EP disclosed
US-10010527-B2 Active metabolite of 1-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole dimesylate monohydrate and dimesylate dihydrate salt of active metabolite SUVEN SCIENCES LIMITED (IN) 2018-07-03 — — US disclosed
US-20180099940-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR ARVINAS OPERATIONS, INC. 2018-04-12 — — US disclosed
US-20170273944-A1 ACTIVE METABOLITE OF 1-[(2-BROMOPHENYL)SULFONYL]-5-METHOXY-3-[(4-METHYL-1-PIPERAZINYL)METHYL]-1H-INDOLE DIMESYLATE MONOHYDRATE AND DIMESYLATE DIHYDRATE SALT OF ACTIVE METABOLITE SUVEN LIFE SCIENCES LIMITED (IN) 2017-09-28 — — US disclosed
US-20170273944-A1 ACTIVE METABOLITE OF 1-[(2-BROMOPHENYL)SULFONYL]-5-METHOXY-3-[(4-METHYL-1-PIPERAZINYL)METHYL]-1H-INDOLE DIMESYLATE MONOHYDRATE AND DIMESYLATE DIHYDRATE SALT OF ACTIVE METABOLITE SUVEN LIFE SCIENCES LIMITED (IN) 2017-09-28 — — US disclosed
WO-2016027276-A1 ACTIVE METABOLITE OF 1-[(2-BROMOPHENYL) SULFONYL]-5-METHOXY-3- [(4-METHYL-1-PIPERAZINYL) METHYL]-1H-INDOLE DIMESYLATE MONOHYDRATE AND DIMESYLATE DIHYDRATE SALT OF ACTIVE METABOLITE SUVEN LIFE SCIENCES LIMITED (IN) 2016-02-25 — — WO disclosed
EP-1057815-B1 CYCLIC AMIDE COMPOUNDS KOWA CO (JP) 2007-09-05 — — EP disclosed
US-6645957-B2 Useful in preventing and treating allergic immunological diseases; treating asthma, atopic dermatitis, allergic rhinitis, inflammatory large bowel disease, contact dermatitis KOWA CO., LTD. (JP) 2003-11-11 — — US disclosed
US-20030096828-A1 Cyclic amide compound KOWA CO., LTD. (JP) 2003-05-22 — — US disclosed
US-6448242-B1 COMPOUND HAVING A STRONG INHIBITORY EFFECT ON THE PRODUCTION OF AN IGE ANTIBODY; ANTIALLERGENS KOWA CO., LTD. (JP) 2002-09-10 — — US disclosed
EP-1057815-A1 CYCLIC AMIDE COMPOUNDS Kowa Co., Ltd. (JP) 2000-12-06 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190241533-A1 NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN FASN, FABP1, SCD USP2 3097/4885SMN1; SMN2 2061/4885CHRM2 4393/4885
US-20030096828-A1 Cyclic amide compound CMA1, HRH2, HRH4 USP2 3827/4885SMN1; SMN2 4567/4885CHRM2 247/4885
US-20180099940-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR AR, ADRM1, CRBN USP2 32/4885SMN1; SMN2 3936/4885CHRM2 3859/4885
US-20170273944-A1 ACTIVE METABOLITE OF 1-[(2-BROMOPHENYL)SULFONYL]-5-METHOXY-3-[(4-METHYL-1-PIPERAZINYL)METHYL]-1H-INDOLE DIMESYLATE MONOHYDRATE AND DIMESYLATE DIHYDRATE SALT OF ACTIVE METABOLITE HTR6, HTR5A, HTR1A USP2 2547/4885SMN1; SMN2 3039/4885CHRM2 138/4885
US-10010527-B2 Active metabolite of 1-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole dimesylate monohydrate and dimesylate dihydrate salt of active metabolite HTR6, HTR5A, HTR1A USP2 2547/4885SMN1; SMN2 3039/4885CHRM2 138/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.